Nutra Pharma Statistics
Total Valuation
Nutra Pharma has a market cap or net worth of 715,973. The enterprise value is 10.64 million.
| Market Cap | 715,973 |
| Enterprise Value | 10.64M |
Important Dates
The next estimated earnings date is Wednesday, April 15, 2026.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nutra Pharma has 7.16 billion shares outstanding.
| Current Share Class | 7.16B |
| Shares Outstanding | 7.16B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.04% |
| Owned by Insiders (%) | 1.02% |
| Owned by Institutions (%) | 0.00% |
| Float | 7.09B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.83 |
| PB Ratio | -0.05 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.27 |
| EV / Sales | 27.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.71 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -88.56% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 5.99% |
| Weighted Average Cost of Capital (WACC) | 24.78% |
| Revenue Per Employee | 65,358 |
| Profits Per Employee | -214,277 |
| Employee Count | 6 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 7.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.00% in the last 52 weeks. The beta is 59.94, so Nutra Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 59.94 |
| 52-Week Price Change | -50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 40.52 |
| Average Volume (20 Days) | 565,017 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Nutra Pharma had revenue of 392,150 and -1.29 million in losses. Loss per share was -0.00.
| Revenue | 392,150 |
| Gross Profit | 247,323 |
| Operating Income | -878,421 |
| Pretax Income | -1.29M |
| Net Income | -1.29M |
| EBITDA | -870,981 |
| EBIT | -878,421 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 54,047 in cash and 9.96 million in debt, with a net cash position of -9.91 million or -0.00 per share.
| Cash & Cash Equivalents | 54,047 |
| Total Debt | 9.96M |
| Net Cash | -9.91M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -14.81M |
| Book Value Per Share | -0.00 |
| Working Capital | -14.89M |
Cash Flow
| Operating Cash Flow | -423,959 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 63.07% |
| Operating Margin | -224.00% |
| Pretax Margin | -327.85% |
| Profit Margin | n/a |
| EBITDA Margin | -222.10% |
| EBIT Margin | -224.00% |
| FCF Margin | n/a |
Dividends & Yields
Nutra Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -179.57% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 18, 2015. It was a reverse split with a ratio of 0.025.
| Last Split Date | May 18, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.025 |
Scores
Nutra Pharma has an Altman Z-Score of -211.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -211.99 |
| Piotroski F-Score | 3 |